Paul Bebbington and Elizabeth Kuipers, two academics whose lives are now impacted by Paul’s diagnosis of Alzheimer’s, offer brave accounts of the day-to-day experiences of living with dementia and being a care provider in an initiative to reduce stigma.
The annual event brings together basic scientists, clinical researchers, early career investigators, clinicians and the care research community to discuss the latest developments and innovation in Alzheimer’s and dementia research.
Promising results from a clinical trial have been published in the peer-reviewed journal of the Alzheimer’s Association.
The US Food and Drug Administration has reviewed clinical trial data for Biogen’s drug aducanumab, which aims to treat cognitive and functional decline in Alzheimer’s disease.
‘Dementia Innovation Readiness Index 2020: 30 Global Cities’ calls strongly for cities to fulfil their commitments under the WHO’s Global action plan on dementia to engage fully with their national dementia plans.
Alzheimer’s Disease International (ADI) launches the world’s most comprehensive report on dementia-related design and the built environment.
At the beginning of World Alzheimer's Month, ADI highlights evidence that the COVID-19 pandemic is leading to extremely high death rates amongst people with dementia globally.
A national dementia plan for China has been officially launched as a part of China’s Action Plan for Healthy China 2030.
Two new reports highlight the challenges faced by health systems in the United States and five European countries to ensure preparedness for potentially imminent Alzheimer’s biomarker and treatment breakthroughs.
The Lancet launches new guidance which reveals that an extended set of 12 modifiable risk factors might prevent or delay up to 40 per cent of dementia cases globally.